LITTLE FALLS, N.J.,
July 10, 2019 /PRNewswire/ -- Cantel
Medical Corp. (NYSE: CMD) announced today that Eric Nodiff, Executive Vice President, General
Counsel and Secretary, will be retiring on July 31, 2019 after 32 years of service to the
Company and Jeff Mann has been
appointed as Senior Vice President, General Counsel and Secretary,
effective August 1, 2019.
Mr. Nodiff informed the Board of Directors earlier this year
that he will retire at the end of the Company's fiscal year and the
Board selected Mr. Mann as his successor.
"Eric has done a fantastic job serving Cantel for more than
three decades with dedication and commitment. Throughout his
tenure, Eric worked tirelessly for all of our stakeholders and in
the best interest of Cantel. He leaves a more resilient company,
positioning us well for the future. I want to thank Eric
personally, and on behalf of the Board, for his contributions to
the Company," said Charles M. Diker,
Chairman of the Cantel Board. "I also would like to congratulate
Jeff on his appointment. I look forward to working with him in his
new role to support the next phase of Cantel's development. Eric
has worked with Jeff since he joined the Company to position him as
a key counselor and contributor to the Board, ensuring a seamless
transition following Eric's retirement."
Mr. Mann joined Cantel in 2018 and has provided oversight of
legal matters pertaining to the Company's domestic commercial
operations. He advocated for corporate governance, provided advice
and counsel to the Executive Leadership Team, Chairman, and Board
of Directors on a wide range of legal matters that impact the
business across all operating units. In his new role, Mr. Mann will
be responsible for oversight and supervision of all legal matters
impacting the Company, including general corporate matters, mergers
and acquisitions, corporate governance and Securities and Exchange
Commission (SEC) compliance.
Prior to Cantel, Mr. Mann held leadership positions at the
Boston Scientific Corporation and served on the Board of Directors
of Preventice Solutions. Mr. Mann holds more than 19 years of law
firm and in-house experience, including leadership on mergers and
acquisitions, intellectual property, securities, corporate
governance, commercial transactions and litigation.
"On behalf of the Board, we are pleased to appoint Jeff to his
new role. Since joining Cantel as Vice President, Deputy General
Counsel last year, Jeff successfully supported the growth of our
business while evaluating potential risk and maintaining careful
governance to ensure that all aspects of the Company are compliant
with relevant laws, policies and regulations," said George Fotiades, President and CEO. "Jeff is a
values-driven leader who has an impressive track record and
demonstrated strong leadership skills over the past year by
providing strategic counsel on a wide range of legal matters,
helping to ensure that Cantel is best equipped to meet our business
objectives. I am confident that Jeff is the right choice to take on
this critical role and we wish him every success."
About Cantel
Cantel is a leading global company dedicated to delivering
innovative infection prevention and control products and services
for patients, caregivers and other healthcare providers which
improve outcomes, enhance safety and help save lives. Our
products include specialized medical device reprocessing systems
for endoscopy and renal dialysis, advanced water purification
equipment, sterilants, disinfectants and cleaners, sterility
assurance monitoring products for hospitals and dental clinics,
disposable infection control products primarily for dental and GI
endoscopy markets, dialysate concentrates, hollow fiber membrane
filtration and separation products. Additionally, we provide
technical service for our products.
For further information, visit the Cantel website at
www.cantelmedical.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cantel-announces-retirement-of-eric-nodiff-general-counsel-jeff-mann-named-successor-300882687.html
SOURCE Cantel Medical Corp.